Skip to main content

Everything we do at Amylyx is centered around those living with neurodegenerative diseases. We are on a mission to discover and develop treatments for relentless neurodegenerative diseases and to help support and create more moments for the neurodegenerative disease community.

FDA Approves RELYVRIO™ (previously known as AMX0035) for the treatment of adults with ALS in the U.S.

Amylyx is proud to announce that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ (sodium phenylbutyrate and taurursodiol [also known as ursodoxicoltaurine]), for the treatment of adults with amyotrophic lateral sclerosis (ALS) in the U.S.

Amylyx initiates Phase 2 clinical trial of AMX0035 in Wolfram syndrome

Amylyx announced that the first participant has been dosed in the Phase 2 HELIOS clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol) for the treatment of Wolfram syndrome (WS). Topline results are anticipated in 2024.

In pursuit of more

Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.

Our ongoing commitment to discovery carries with it a responsibility to be transparent, set realistic expectations, and work together to make an impact. Learn more about our unique culture, approach to clinical trials and more.

Latest News